GlassScriptPhysician profile
Shiny E Saju
NPI 1881125185
$3,159.82
in general payments reported to CMS, 2019-2025
27 companies · $671 in 2025
The $671 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $546 · 2022: $395 · 2023: $598 · 2024: $950 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $606.04 | 2023-2025 | Sonicision, Signia |
| Novo Nordisk INC | $444.23 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $311.83 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Integra Lifesciences Corporation | $308.79 | 2022-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Boston Scientific Corporation | $245.60 | 2024-2025 | Spyglass Discover |
| W. L. Gore & Associates, INC. | $243.85 | 2021-2024 | Seamguard Staple Line Reinforcement |
| Janssen Pharmaceuticals, INC | $219.28 | 2021-2022 | |
| Kerecis Limited | $145.89 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Vertex Pharmaceuticals Incorporated | $125.01 | 2024-2025 | |
| Ardelyx, INC. | $71.13 | 2024 | Ibsrela |
| Myriad Genetic Laboratories, INC. | $59.54 | 2021 | |
| Lemaitre Vascular, INC. | $50.29 | 2023-2025 | Artegraft Vascular Graft |
| Paratek Pharmaceuticals, INC. | $37.94 | 2021 | |
| Organogenesis INC. | $37.71 | 2023 | Puraply |
| Currax Pharmaceuticals LLC | $29.34 | 2022-2023 | Contrave |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $28.54 | 2021-2024 | Grafix Pl, Stravix Pl |
| Shockwave Medical, INC | $26.92 | 2025 | |
| Tela Bio, INC. | $25.13 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Solventum Corporation | $24.44 | 2024 | Activ.A.C. |
| Pacira Pharmaceuticals Incorporated | $20.92 | 2025 | Exparel |
| Acera Surgical, INC. | $18.05 | 2025 | Restrata Wound Matrix |
| Ethicon US, LLC | $16.87 | 2021 | |
| Chiesi USA, INC. | $13.48 | 2021 | |
| Kci USA, INC. | $12.69 | 2022 | |
| Endo Pharmaceuticals INC. | $12.58 | 2021 | |
| Angiodynamics, INC. | $12.08 | 2022 | |
| Monaghan Medical Corporation | $11.65 | 2023 | Aerochamber |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiny Saju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.